Benchtop Western Blot Processor Market Forecasts to 2030 – Global Analysis By Type (Dry Blotting Systems, Semi-Dry Blotting Systems and Other Types), Application (Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Research & Academic Ins

Benchtop Western Blot Processor Market Forecasts to 2030 – Global Analysis By Type (Dry Blotting Systems, Semi-Dry Blotting Systems and Other Types), Application (Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Research & Academic Institution and Other Applications) and By Geography

According to Stratistics MRC, the Global Benchtop Western Blot Processor Market is accounted for $1000.42 million in 2023 and is expected to reach $1736.89 million by 2030 growing at a CAGR of 8.2% during the forecast period. In molecular biology, biochemistry, and immunogenetics, the western blot is a frequently used experimental technique. Moreover, the basic idea is to use particular antibodies to stain cells or biological tissue samples that are being processed through gel electrophoresis. Analyze the staining location and depth to learn more about the expression of particular proteins in the examined cells or tissues.

According to scientific research practices, Western blotting, also known as protein immunoblotting is a widely employed technique for detecting and analyzing specific proteins in complex biological samples.

Market Dynamics

Driver

Growing life sciences research

Precise protein analysis is becoming more and more necessary as the life sciences sector—which includes fields like cancer biology, neuroscience, and genomics—expands quickly. Bench top processors are essential in these research domains because Western blotting is still a fundamental technique. Moreover, bench top processors are a major factor in the efforts of researchers to optimize the Western blotting procedure because they provide automation, consistency, and increased efficiency.

Restraint

Operating and maintenance costs

Even after the initial outlay, continuing upkeep and running costs can be difficult. Periodic maintenance, calibration, and replacement of consumables like gels, membranes, and antibodies are necessary for bench top Western blot processors. Additionally, the price of electricity and other utilities that are required for operation can also raise the total cost. Over time, these ongoing costs may put a strain on research facilities' budgets.

Opportunity

Improvements in features and technology

Bench top Western blot processor innovation is still being made possible by the rapid advancement of technology. Furthermore, manufacturers can take advantage of opportunities to add more sophisticated features to these instruments, like increased automation, quicker processing, and better data analysis. In this competitive market, companies can differentiate themselves by creating user-friendly interfaces, cloud-based data storage solutions, and remote monitoring.

Threat

Budget limitations in medical and research

Funding for research can be scarce, particularly in academic and nonprofit research organizations. Budgetary restrictions are another issue facing the healthcare sector. Moreover, bench top Western blot processors can be expensive up front, which could put off or discourage prospective customers from making a purchase. Budget cuts in healthcare and research can have a big effect on the market during uncertain economic times and limit the use of these instruments.

Covid-19 Impact

The market for bench top Western blot processors was greatly impacted by the COVID-19 pandemic. The adoption of these instruments slowed down as a result of disruptions to global supply chains, temporary closures of research facilities, and the allocation of healthcare resources to pandemic-related activities. A lot of labs postponed capital expenses because of financial limitations and the unpredictability of the pandemic, including buying new bench top Western blot processors. However, the development of diagnostic tests and the significance of protein analysis in the study of SARS-CoV-2 led to the persistence of demand in some market segments.

The Semi-Dry Blotting Systems segment is expected to be the largest during the forecast period

The Western blotting systems market is expected to have the largest share in the semi-dry blotting systems segment. These systems are well-liked by laboratories and researchers because they provide a good balance between speed and efficiency. Compared to conventional wet blotting systems, semi-dry blotting allows for faster transfers while using less buffer and laboratory space. Semi-dry blotting combines the benefits of both wet and dry blotting methods. Moreover, the popularity of this segment can be attributed to its affordability, quick transfer times, and user-friendliness, making it a favored choice for many protein analysis applications.

The Pharmaceutical and Biotechnology Companies segment is expected to have the highest CAGR during the forecast period

In the market for benchtop Western blot processors, pharmaceutical and biotechnology companies are anticipated to have the highest CAGR. Precise protein analysis is necessary for the R&D, drug discovery, and bio manufacturing initiatives that these companies regularly fund. The demand for bench top Western blot processors is driven by the need for quick and dependable results in these industries, as well as the growing trend toward automation. The high growth of pharmaceutical and biotechnology companies in this market can be attributed to their early adoption of sophisticated laboratory equipment. Furthermore, the development of Western blotting applications is being driven by advances in personalized medicine and biologics, which make these markets important growth drivers.

Region with largest share

In general, the benchtop Western blot processor market is anticipated to hold the largest share in the North American region. The pharmaceutical and biotechnology industries, academic institutions, and diagnostic labs that are well-established in North America are the ones who need these instruments for research and analysis of proteins. Moreover, prominent manufacturers, a culture of technological innovation, and robust research funding are additional advantages for the region. North America holds a commanding market share in benchtop Western blot processors due to a combination of these factors.

Region with highest CAGR

In the market for benchtop Western blot processors, the Asia-Pacific area is growing at the highest CAGR. This growth is being driven by the region's growing number of academic and research institutions, growing biotechnology and pharmaceutical sectors, and rising investments in life sciences research. In addition, the need for Western blotting equipment has increased due to the healthcare industry's explosive growth and rising awareness of sophisticated laboratory techniques. Additionally, the changing economic conditions in the Asia-Pacific area, especially in China and India, have made the region a major growth engine for the market for benchtop Western blot processors.

Key players in the market

Some of the key players in Benchtop Western Blot Processor market include Bio-Rad Laboratories, Thermo Fisher Scientific, Bio-Techne, Merck, PerkinElmer, Gen Script Biotech, ATTO Corporation, Tecan, Life Technologies, Euroimmun, Precision Biosystems, Cytoskeleton, LI-COR Biosciences, Cytiva and Molecular Devices.

Key Developments

In July 2023, Bio-Rad Laboratories, Inc and QIAGEN N.V., announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.

In June 2023, Bio-Techne announced that it has reached an agreement to acquire Tolochenaz, Switzerland-based Lunaphore, a developer of fully automated spatial biology products. Bio-Techne said that it expects to close the deal by the end of September, in the first quarter of its fiscal 2024. Wenger Plattner is Bio-Techne's legal counsel. Bourgeois Avocat is legal counsel to Lunaphore, while UBS Investment Bank is Lunaphore’s financial advisor.

In May 2023, Pfizer and Thermo Fisher Scientific Inc. announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable. Access to local NGS testing can help to provide faster analysis of associated genes, empowering healthcare providers to select the right therapy for that individual patient.

Types Covered
• Dry Blotting Systems
• Semi-Dry Blotting Systems
• Other Types

Applications Covered
• Diagnostic Laboratories
• Pharmaceutical and Biotechnology Companies
• Research & Academic Institution
• Other Applications

Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements